PropertyValue
?:abstract
  • • Despite the burden of gene therapy trials for DMD patients there is great enthusiasm. • Collaborating with relevant bodies (pharmacy) at an early stage can accelerate progress. • A hub and spoke model may be an option for delivering clinical trials and follow up care.
is ?:annotates of
?:creator
?:doi
?:doi
  • 10.1016/j.nmd.2020.10.001
?:journal
  • Neuromuscul_Disord
?:license
  • no-cc
?:pdf_json_files
  • document_parses/pdf_json/697c3fe8bf047bdd6f18e62e8b2e0e28ed6f099b.json
?:pmc_json_files
  • document_parses/pmc_json/PMC7564510.xml.json
?:pmcid
?:pmid
?:pmid
  • 33158687.0
?:publication_isRelatedTo_Disease
?:sha_id
?:source
  • Elsevier; Medline; PMC
?:title
  • Gene Therapy in Duchenne muscular dystrophy: Identifying and preparing for the challenges ahead
?:type
?:year
  • 2020-10-16

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/24hl2zy1>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/24hl2zy1>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all